『Pure Global's Guide to Indonesian Market Access: Choosing Your Local Authorized Representative in the Heart of ASEAN』のカバーアート

Pure Global's Guide to Indonesian Market Access: Choosing Your Local Authorized Representative in the Heart of ASEAN

Pure Global's Guide to Indonesian Market Access: Choosing Your Local Authorized Representative in the Heart of ASEAN

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

 Navigating the Indonesian MedTech market presents a critical challenge for foreign manufacturers: the mandatory appointment of a Local Authorized Representative (LAR). This isn't merely an administrative step; it's a strategic decision that defines who controls your product's registration license and, ultimately, your access to one of Southeast Asia's largest markets. This episode of ASEAN MedTech Insights explores the two primary options for an LAR—appointing your distributor versus partnering with an independent third party. We uncover the hidden risks of tying your regulatory license to a commercial partner and explain why an independent representative provides the flexibility and control necessary for long-term success and scalability in the complex Indonesian archipelago. For example, consider a European diagnostics firm that allowed its sole distributor in Indonesia to hold its product licenses. When a disagreement arose over sales performance, the firm decided to switch partners, only to find their licenses were held hostage by the original distributor. This forced them into a costly, two-year re-registration process, effectively locking them out of the market and forfeiting significant revenue. Key Takeaways: * Why is appointing a Local Authorized Representative a mandatory first step for selling medical devices in Indonesia? * What are the hidden risks of allowing your distributor to be your legal license holder? * How does the ownership of the registration license (Izin Edar) impact your ability to change commercial partners? * What happens to your market access if your relationship with a distributor-representative ends poorly? * Why is an independent representative model considered a safer, more flexible strategy for market entry? * How can you build a multi-distributor network in Indonesia without re-registering your product for each one? * What is the strategic difference between regulatory control and commercial strategy in the ASEAN context? At Pure Global, we provide MedTech and IVD companies with end-to-end regulatory solutions, including acting as your independent Local Authorized Representative in Indonesia and over 30 markets worldwide. Our combination of local expertise and advanced AI tools streamlines your global market access. To maintain full control of your assets and build a flexible market strategy, contact us at info@pureglobal.com or visit https://pureglobal.com/.
まだレビューはありません